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Abstract
BACKGROUND—Ebola virus has been detected in the semen of men after their recovery from 
Ebola virus disease (EVD). We report the presence of Ebola virus RNA in semen in a cohort of 
survivors of EVD in Sierra Leone.
METHODS—We enrolled a convenience sample of 220 adult male survivors of EVD in Sierra 
Leone, at various times after discharge from an Ebola treatment unit (ETU), in two phases (100 
participants were in phase 1, and 120 in phase 2). Semen specimens obtained at baseline were 
tested by means of a quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay 
with the use of the target sequences of NP and VP40 (in phase 1) or NP and GP (in phase 2). This 
study did not evaluate directly the risk of sexual transmission of EVD.
RESULTS—Of 210 participants who provided an initial semen specimen for analysis, 57 (27%) 
had positive results on quantitative RT-PCR. Ebola virus RNA was detected in the semen of all 7 
men with a specimen obtained within 3 months after ETU discharge, in 26 of 42 (62%) with a 
specimen obtained at 4 to 6 months, in 15 of 60 (25%) with a specimen obtained at 7 to 9 months, 
in 4 of 26 (15%) with a specimen obtained at 10 to 12 months, in 4 of 38 (11%) with a specimen 
obtained at 13 to 15 months, in 1 of 25 (4%) with a specimen obtained at 16 to 18 months, and in 
no men with a specimen obtained at 19 months or later. Among the 46 participants with a positive 
result in phase 1, the median baseline cycle-threshold values (higher values indicate lower RNA 
values) for the NP and VP40 targets were lower within 3 months after ETU discharge (32.4 and 
31.3, respectively; in 7 men) than at 4 to 6 months (34.3 and 33.1; in 25), at 7 to 9 months (37.4 
and 36.6; in 13), and at 10 to 12 months (37.7 and 36.9; in 1). In phase 2, a total of 11 participants 
had positive results for NP and GP targets (samples obtained at 4.1 to 15.7 months after ETU 
discharge); cycle-threshold values ranged from 32.7 to 38.0 for NP and from 31.1 to 37.7 for GP.
CONCLUSIONS—These data showed the long-term presence of Ebola virus RNA in semen and 
declining persistence with increasing time after ETU discharge. (Funded by the World Health 
Organization and others.)
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On March 17, 2016, The World Health Organization (WHO), the Chinese Center for Disease 
Control and Prevention (China CDC), and the Centers for Disease Control and Prevention 
(CDC) joined the government of Sierra Leone in marking the end of the most recent flare-up 
of Ebola virus disease (EVD) in the country; and in June 2016, the WHO declared the end of 
Ebola virus (EBOV) transmission in the Republic of Guinea and in Liberia.1 Unprecedented 
in its magnitude, this epidemic was responsible for the deaths of at least 3590 people in 
Sierra Leone.1
The main mode of transmission of EBOV is direct contact with the blood or body fluids of a 
person with EVD or from the body of a person who died from EVD.2,3 In addition, EBOV 
can persist in the body fluids of survivors of EVD during convalescence,4,5 and this 
persistence could result in transmission of the virus. The potential for the persistence of 
EBOV, particularly in the semen of male survivors, arouses concern about the risk of sexual 
transmission.6
Previously, EVD survivors had been advised to practice sexual abstinence or to use a 
condom during sexual activity for 3 months after recovery. These recommendations were 
based on EBOV-detection results from semen specimens that were obtained from eight 
survivors of EVD or Marburg virus disease in previous epidemics,5,7–11 in which the longest 
period that infectious virus was detected in semen after symptom onset was 82 days.5,7
In March 2015, a woman in Liberia received a diagnosis of EVD, and her only potential 
exposure that could be ascertained was sexual contact with a male survivor of EVD. Further 
investigation showed EBOV RNA in the survivor’s semen 199 days after the onset of his 
symptoms, and the genetic sequence matched the sequence in the sample obtained from the 
case patient.12 Although no infectious virus was detected in this semen specimen, the 
possibility that infectious EBOV could persist in the semen of survivors approximately 6 
months after symptom onset prompted the WHO and the CDC to revise their guidelines 
regarding the length of time that survivors should practice safer sex (in particular, with the 
use of condoms) or sexual abstinence.13,14
A study that was published in August 2016 described 429 survivors of EVD who were 
enrolled in the National Semen Testing Program in Liberia.15 The authors found that the 
longest interval between discharge from an Ebola treatment unit and a positive result on 
reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay was 565 days (18.5 
months). Furthermore, a report from Guinea presented data on a male survivor in whom 
EBOV was detected by means of PCR in semen 531 days (17.4 months) after symptom 
onset, and sequencing data provided evidence of sexual transmission approximately 470 
days (15.4 months) after symptom onset.16 Cases that have been linked to sexual contact 
with survivors of EVD from the West African outbreak of EVD have not been systematically 
documented, and fewer than 20 cases in total have been reported (Knust B, CDC; Formenty 
P, WHO: personal communication).
The Sierra Leone Ministry of Health and Sanitation, in collaboration with the Sierra Leone 
Ministry of Defense; the Sierra Leone Ministry of Social Welfare, Gender, and Children’s 
Affairs; the WHO; the CDC; and later the China CDC initiated a cohort study investigating 
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the duration of virus persistence in the body fluids of survivors of EVD in Sierra Leone. This 
article describes the participants’ characteristics at entry in the cohort of male survivors of 
EVD whose semen was tested by means of RT-PCR; it is an update of a preliminary report, 
which is available with the full text of this article at NEJM.org.
METHODS
STUDY DESIGN, CONDUCT, AND OVERSIGHT
This was an observational cohort study of a convenience sample of 220 male survivors of 
EVD in Sierra Leone.17 The study was designed by the Sierra Leone Ministry of Health and 
Sanitation; the Sierra Leone Ministry of Social Welfare, Gender, and Children’s Affairs; the 
WHO; and the CDC. The Sierra Leone Ministry of Defense, the Sierra Leone Ministry of 
Health and Sanitation, the WHO, the CDC, and the China CDC gathered the data. Semen 
specimens were analyzed by the CDC during phase 1 and by the China CDC during phase 2 
(phases 1 and 2 are defined below). Data analysis was performed and supervised by the 
WHO, the CDC, and the China CDC. Manuscript planning and drafting were overseen and 
performed by the Sierra Leone Ministry of Health and Sanitation, the WHO, the CDC, and 
the China CDC. The overall coordination of the study was ensured by WHO, in 
collaboration with the Sierra Leone Ministry of Health and Sanitation and the Sierra Leone 
Ministry of Defense. All the research activities were performed in accordance with all the 
applicable laws, regulations, and policies related to the protection of human participants and 
animals. The research protocol was reviewed and approved by the Sierra Leone Ethical 
Review Board and the WHO Ethical Review Committee. Participants received a 
compensation for each visit to the study site. A complete list of the members of the Sierra 
Leone Ebola Virus Persistence Study Group is provided in the Appendix, available with the 
full text of this article at NEJM.org.
STUDY POPULATION, SAMPLING, AND ELIGIBILITY CRITERIA
The 220 male survivors of EVD who were included in the cohort were identified at 
informational events that were held in conjunction with local associations for survivors of 
EVD.17 Men who indicated their interest in participation were offered enrollment in the 
study. Recruitment was conducted in two phases. Phase 1 enrolled 100 male participants 
(who had only semen tested) who had been recruited from the Western Area District in the 
capital of Freetown, and phase 2 enrolled 120 male participants (who had semen and other 
body fluids tested; only the results of the semen testing are reported in this article) who had 
been recruited from the Western Area District and from Lungi (Port Loko District).
Participants were eligible for inclusion if they were men, 18 years of age or older, and could 
provide an official EVD survivor certificate that had been issued by the Sierra Leone 
Ministry of Health and Sanitation. Such certificates were provided to persons with 
laboratory-confirmed cases of EVD when they were discharged from an Ebola treatment 
unit. Entry in the study began after an informed-consent form was signed; enrollment was 
followed by a standardized questionnaire and specimen collection.
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DATA COLLECTION AND COUNSELING
At the time of enrollment, all the participants were administered a standardized 
questionnaire by a member of the study team in order to gather information about their 
sociodemographic characteristics, EVD episode, self-reported health status, and sexual 
behavior. The date of discharge from an Ebola treatment unit was ascertained from the 
participants’ EVD survivor certificates.
Participants received pre–Ebola-test counseling at the time of enrollment and post–Ebola-
test counseling 2 weeks later, when they received their individual RT-PCR results. The 
counseling included information about the test performed, the meaning of the results, and 
education about sexual risk-reduction practices, including appropriate condom use and 
disposal.18 Participants were referred to a clinic for survivors of EVD if needed, as 
determined by the trained medical study staff, or requested.
SPECIMEN COLLECTION AND LABORATORY ANALYSES
Only semen specimens were obtained and tested for EBOV persistence in phase 1, and 
specimens of semen and other body fluids were obtained and tested for EBOV persistence in 
phase 2. At enrollment, participants were asked to provide a semen specimen in a private 
room and were provided instructions to ensure that proper infection-control procedures were 
followed. Trained counselors also offered participants a voluntary, confidential rapid test for 
the human immunodeficiency virus (HIV) in accordance with the national testing algorithm. 
However, this article focuses only on the semen testing.
Semen specimens were refrigerated (at 5 to 8°C) for no longer than 3 days. The semen 
specimens that had been obtained from phase 1 participants were transported to and tested at 
the CDC field laboratory in Bo District, Sierra Leone, and the semen specimens that had 
been obtained from phase 2 participants were transported to and tested at the China CDC Jui 
Laboratory in Freetown.
In phase 1, quantitative RT-PCR assays were performed that targeted EBOV NP and VP40 
gene targets and the human β2-microglobulin (B2M) gene (Thermo Fisher Scientific), as 
described previously.19–21 A specimen was considered to be positive if the NP and VP40 
gene targets were both detected within 40 cycles of replication, and the results were 
considered to be indeterminate if one of the NP or VP40 gene targets was detected but not 
both.
In phase 2, a double-channel quantitative RT-PCR detection kit was used to detect EBOV 
NP and GP genes22 and B2M. A specimen was considered to be positive if either or both of 
the NP or GP gene targets were detected within 38 cycles of replication. There was no 
indeterminate result. For the semen samples in both phase 1 and phase 2, the specimen was 
considered to be negative if both EBOV gene targets were not detected and the findings with 
respect to B2M status were positive. Amplification of B2M served as an extraction control 
and RNA quality control.
The cycle-threshold value for each gene target is reported as the number of replication cycles 
that had occurred when the target was first detected. Cycle-threshold values have an inverse 
Deen et al. Page 4
N Engl J Med. Author manuscript; available in PMC 2018 February 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
association with RNA quantity, such that lower cycle-threshold values indicate higher 
quantities of RNA in given specimens.23
STATISTICAL ANALYSIS
For the analysis of EBOV persistence in semen, baseline data from phase 1 and phase 2 were 
pooled into one sample of 220 male survivors of EVD. The descriptive analysis that we 
present here focuses on two aspects: the sociodemographic data of all the participants, 
according to the site of origin (from Freetown, an urban area; and from Lungi, a semiurban 
area); and the number of participants who had a positive, indeterminate, or negative result on 
quantitative RT-PCR at enrollment, according to the number of days between the date of 
discharge from an Ebola treatment unit and the date that the semen specimen was obtained. 
When the duration between discharge and the date of the specimen collection was reported 
in months, a 30-day interval per month applied. We report the median cycle-threshold 
values, according to months after discharge, with the range (minimum and maximum) of 
values that was observed for the NP and VP40 gene targets (phase 1) and for the NP and GP 
gene targets (phase 2). For other quantitative variables, means with standard deviations and 
medians with interquartile ranges are reported. Data analysis was performed with the use of 
SAS/STAT software (SAS Institute).24
RESULTS
STUDY PARTICIPANTS
A total of 220 male survivors of EVD were enrolled: 100 participants were enrolled in the 
Free-town urban site during phase 1 (May 27, 2015, through July 7, 2015), and 120 
participants (60 in the Freetown urban site and 60 in the semi-urban Lungi site) during phase 
2 (November 11, 2015, through May 12, 2016).
The sociodemographic characteristics of the study participants are presented in Table 1, 
according to study site and phase. There were key differences between the sites. As 
compared with the participants from the Freetown urban site, participants from the Lungi 
semiurban site were slightly older, were more likely to have received no formal education, 
were more often engaged in a long-term relationship or married, reported that there were 
more people in their household, and reported that more household members had been 
infected with EBOV. Among 195 men (89%) who agreed to be tested for HIV, 1 was found 
to be HIV-positive.
Overall, the mean (±SD) duration between the date of discharge from an Ebola treatment 
unit and the baseline visit was 10.0±4.9 months. This duration was longer among the 
participants in phase 2 of the study (11.5±3.2 months in Freetown and 15.6±2.9 months in 
Lungi) than among those in phase 1 (5.9±1.9 months in Freetown) because of delayed 
recruitment that started after the epidemic had ended (Table 1).
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DETECTION OF EBOLA VIRUS RNA IN SEMEN
Of the 210 participants who provided a semen specimen for analysis at study entry, 57 
(27%) had positive results on quantitative RT-PCR (Table 1); 46 were participants from 
phase 1 of the study and 11 were from phase 2. Overall, EBOV RNA was detected in semen 
in all 7 men from whom a specimen was obtained within 3 months after discharge from an 
Ebola treatment unit, in 26 of 42 (62%) from whom a specimen was obtained 4 to 6 months 
after discharge, in 15 of 60 (25%) from whom a specimen was obtained 7 to 9 months after 
discharge, in 4 of 26 (15%) from whom a specimen was obtained 10 to 12 months after 
discharge, in 4 of 38 (11%) from whom a specimen was obtained 13 to 15 months after 
discharge, and in 1 of 25 (4%) from whom a specimen was obtained 16 to 18 months after 
discharge; all 12 semen specimens that were obtained 19 months or more after discharge 
were negative (Fig. 1). In addition, the results of 4 semen specimens obtained at 4 to 6 
months after discharge from an Ebola treatment unit, 7 obtained at 7 to 9 months after 
discharge, and 2 obtained at 10 to 12 months after discharge were indeterminate (only one 
target positive) when the NP and VP40 targets were assessed. The proportion of men with 
semen specimens that tested negative by means of quantitative RT-PCR increased with the 
duration between the date of discharge from an Ebola treatment unit and the date that the 
specimen was obtained.
In phase 1, the median cycle-threshold values of the detected NP and VP40 target genes in 
semen specimens increased over time after discharge from an Ebola treatment unit. For 
specimens obtained within 3 months after discharge, the values were 32.4 with the NP gene 
target and 31.3 with the VP40 gene target; for those obtained at 4 to 6 months, the values 
were 34.3 and 33.1, respectively; and for those obtained at 7 to 9 months, the values were 
37.4 and 36.6, respectively (Table 2). For a single baseline specimen that was obtained at 10 
to 12 months, the cycle-threshold values were 37.7 for NP and 36.9 for VP40. A total of 11 
participants in phase 2 tested positive for NP and GP target genes (these participants were 
recruited at a later stage after discharge from an Ebola treatment unit), and the cycle-
threshold values ranged from 32.7 to 38.0 for the NP target gene and from 31.1 to 37.7 for 
the GP target gene; the numbers were too small for us to investigate trends over time.
The longest time that was reported between discharge from an Ebola treatment unit and the 
initial time that the semen specimen was obtained in a man who tested positive was 470 days 
(15.7 months). Conversely, the shortest time after discharge that a participant had a negative 
result on an initial semen specimen was 100 days (3.3 months). Indeterminate results were 
encountered in 13 initial specimens that were obtained in the range of 144 to 335 days (4.8 
to 11.2 months) after discharge from an Ebola treatment unit.
DISCUSSION
We conducted a cross-sectional analysis involving 220 male survivors of EVD who had 
enrolled in a prospective observational cohort for the investigation of EBOV persistence in 
semen. Participants were recruited in two different phases and at different study sites: 
Freetown in the Western Area District, and Lungi in the Port Loko District.
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Sampling was not random, and further analysis was conducted to understand how the group 
of participants that was recruited in this study is representative of the overall population of 
survivors of EVD in Sierra Leone. The participants in phase 1 were recruited between 4 and 
6 months earlier than those in phase 2. The differences between the participants in phase 1 
and those in phase 2 are therefore biased by this difference in the number of months after 
discharge at the time of enrollment.
In the preliminary report, the semen RT-PCR test results at baseline were provided with 
respect to time since symptom onset, whereas in the current analysis we used time after 
discharge from an Ebola treatment unit. This change was made because discrepancies were 
found in the symptom-onset date for the cohort during data cleaning, and the team opted to 
use the discharge date instead in order to ensure validity. Although this change affected the 
distribution and the longest duration to a negative result at study entry, the date of discharge 
was retained as a reference for the analysis. Therefore, the exact number of days of RNA 
persistence in semen cannot be directly compared between the two reports.
All seven participants who provided a semen specimen during the first 3 months after 
discharge from an Ebola treatment unit had positive results on quantitative RT-PCR. This 
finding is consistent with those of previous studies involving male survivors of the Ebola and 
Marburg virus diseases. The percentage of male participants with positive results declined 
with the increased time between the date of discharge and the date of enrollment in the 
study. Because the longitudinal analysis of EBOV RNA shedding in semen over time is 
ongoing, we do not yet know how long this detection will continue. Follow-up analysis is 
ongoing to elucidate the dynamic of the clearance of EBOV in semen at different points in 
time.
The quantitative RT-PCR assays that were used in this study to test semen specimens are the 
same that were used to test blood specimens obtained from patients with suspected EVD. 
The assays are highly sensitive,19,22 and the detection of viral RNA does not necessarily 
indicate that infectious virus is present in blood or semen.21,25,26
We found that the median cycle-threshold values for the EBOV gene targets increased 
(indicating lower RNA values) when the analysis was performed with samples that had been 
obtained from participants who had a longer duration between the date of discharge from an 
Ebola treatment unit and the date of entry in the study. The cycle-threshold values that were 
obtained for EBOV target genes have been shown to correlate with viral load in blood,23 
with an increasing cycle-threshold value indicating a decrease in the viral load. However, the 
detection of viral RNA does not necessarily indicate that infectious virus is present. A 
limited study that examined the relationship between cycle-threshold values and virus 
isolation did not detect infectious virus in blood specimens obtained from patients with EVD 
when cycle-threshold values were greater than 35.5 with the NP gene target.25 Similarly, in 
semen obtained from survivors of EVD that was tested in the United States, the highest 
cycle-threshold value for the NP target gene that yielded a virus isolate was 30; a total of 12 
specimens with a cycle-threshold value greater than 30 did not yield any virus isolates.27 In 
this study cohort, we found that men provided specimens that were positive on quantitative 
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RT-PCR several months after the discharge date and that the cycle-threshold values 
increased with time.
The potential contribution of sexual transmission to the scale of the epidemic is largely 
unknown, and we do not yet have sufficient information to assess the risk of transmission by 
means of sexual intercourse, oral sex, or other sex acts from men with viable virus in their 
semen. However, the unprecedented number of more than 16,000 survivors of EVD across 
Sierra Leone, Guinea, and Liberia, roughly half of whom are male, creates the potential for 
transmission and the initiation of new chains of transmission, even months after the outbreak 
has ended. Even though only rare cases of EVD have been linked to sexual transmission, 
research is needed to investigate whether infectious virus may be present in vaginal fluid or 
other body fluids after recovery, and the testing of additional body fluids in both male and 
female survivors is planned. It is also important to note that the three affected countries have 
a very low rate of HIV infection and other sexually transmitted infections, with a prevalence 
of HIV infection among adults of 1.3% in Sierra Leone,28 1.6% in Guinea,29 and 1.1% in 
Liberia30; these rates may also have influenced risks of EBOV sexual transmission.
Understanding the duration of Ebola virus shedding in survivors of EVD, and preventing 
further transmission, was essential for ultimately controlling the Ebola epidemic in West 
Africa. On the basis of the preliminary report of this study, the WHO, the CDC, and other 
partners engaged with the Ministries of Health of the three affected countries to establish 
and implement national semen-testing programs and preventive behavioral counseling. 
These efforts were essential to help survivors of EVD who participated in the initiatives, and 
they may have mitigated the risks of sexual transmission. Such programs helped men and 
women to understand their individual risk and to take appropriate measures to protect their 
sexual partners, specifically with regard to condom use and disposal. Such programs could 
also provide links to care and counseling programs for survivors. At the beginning of the 
epidemic and throughout the period that it lasted, survivors of EVD were stigmatized. There 
were instances when survivors were denied access to their homes after being discharged 
from the Ebola treatment unit. After the epidemic, the level of stigmatization of survivors 
has decreased.31,32 Currently, most survivors of EVD have been reintegrated into their 
communities, but health care access for survivors of EVD remains a concern.33,34 Because 
the implementation of semen-testing programs has been limited, outreach activities are 
needed to provide education regarding recommendations and risks to survivor communities 
and sexual partners of survivors in a way that does not further stigmatize the community of 
survivors of EVD. Due respect and continuing efforts that have strong sustainable support 
from within the local communities are crucial in mitigating negative effects in terms of 
further stigma attached to survivors.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Results on Reverse Transcriptase–Polymerase Chain Reaction in Semen Specimens 
Obtained at Baseline from Survivors of Ebola Virus Disease, According to Time after Discharge 
from an Ebola Treatment Unit (ETU)
An indeterminate result indicates that one of the gene targets was detected and one was not 
detected; this finding applies only to the assay from the Centers for Disease Control and 
Prevention that was used during phase 1.
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Table 1
Characteristics of Study Participants at Baseline, According to Study Site and Phase.*
Characteristic Freetown Site Lungi Site Total
Phase 1 (N = 100) Phase 2 (N = 60) Phase 2 (N = 60) Phases 1 and 2 (N = 
220)
Recruitment period May 27, 2015–July 
7, 2015
Nov. 11, 2015–Feb. 
17, 2016
Feb. 3, 2016–May 12, 
2016
May 27, 2015–May 
12, 2016
Age
 Mean — yr 29.7±8.4 31.3±8.3 34.8±11.5 31.5±9.5
 Median (interquartile range) — yr 27 (24–34) 30 (25–36) 34 (26–43) 29 (25–36)
 Distribution — no./total no. (%)
  ≤25 yr 36/99 (36) 18/60 (30) 13/60 (22) 67/219 (31)
  26–35 yr 44/99 (44) 25/60 (42) 22/60 (37) 91/219 (42)
  >35 yr 19/99 (19) 17/60 (28) 25/60 (42) 61/219 (28)
Highest level of education — no. (%)†
 No education 14 (14) 10 (17) 19 (32) 43 (20)
 Primary education 49 (49) 13 (22) 8 (13) 70 (32)
 Secondary education 37 (37) 37 (62) 33 (55) 107 (49)
Marital status — no. (%)
 Married or in a long-term relationship 51 (51) 31 (52) 40 (67) 122 (55)
 Single, divorced, widowed, or separated 49 (49) 29 (48) 20 (33) 98 (45)
Current household size, including self — 
no./total no. (%)
 ≤4 persons 32/100 (32) 17/57 (30) 7/59 (12) 56/216 (26)
 5–8 persons 30/100 (30) 35/57 (61) 8/59 (14) 73/216 (34)
 9–12 persons 27/100 (27) 4/57 (7) 12/59 (20) 43/216 (20)
 >12 persons 11/100 (11) 1/57 (2) 32/59 (54) 44/216 (20)
No. of household members with EVD, 
excluding self — no. (%)
 0 36 (36) 16 (27) 6 (10) 58 (26)
 1 or 2 34 (34) 16 (27) 11 (18) 61 (28)
 3 or 4 15 (15) 13 (22) 14 (23) 42 (19)
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Characteristic Freetown Site Lungi Site Total
Phase 1 (N = 100) Phase 2 (N = 60) Phase 2 (N = 60) Phases 1 and 2 (N = 
220)
 ≥5 15 (15) 15 (25) 29 (48) 59 (27)
Duration between ETU discharge and 
semen-specimen collection
 Mean — mo 5.9±1.9 11.5±3.2 15.6±2.9 10.0±4.9
 Median (interquartile range) — mo 6.2 (4.5–7.1) 11.3 (9.0–14.0) 15.5 (13.7–17.5) 8.6 (6.2–14.2)
 Range — mo 1.3–11.2 4.1–19.3 8.5–22.3 1.3–22.3
 No semen specimen — no. 2 5 3 10
Result of Ebola RT-PCR semen testing at 
baseline — no./total no. (%)
 Positive 46/98 (47) 8/55 (15) 3/57 (5) 57/210 (27)
 Indeterminate‡ 13/98 (13) 0/55 0/57 13/210 (6)
 Negative 39/98 (40) 47/55 (85) 54/57 (95) 140/210 (67)
*
Plus–minus values are means ±SD. The Freetown site is in an urban area, and the Lungi site in a semiurban area. Percentages may not total 100 
because of rounding. ETU denotes Ebola treatment unit, EVD Ebola virus disease, and RT-PCR reverse transcriptase–polymerase chain reaction.
†
Primary education was defined as 1 to 8 years of school, and secondary education as more than 8 years of school.
‡An indeterminate result indicates that one of the gene targets was detected and one was not detected; this finding applies only to the assay from 
the Centers for Disease Control and Prevention that was used during phase 1.
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